NCT01524991 - First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

July 15, 2017

Study Completion Date

December 31, 2018

Conditions

Urothelial Carcinoma

Interventions

DRUG

Gemcitabine

Gemcitabine 1000 mg/m2 Days 1 \& 8 (all cycles)

DRUG

Cisplatin

Cisplatin 70 mg/m2 Day 1 (all cycles)

DRUG

Ipilimumab

Ipilimumab 10 mg/kg Day 1 (start cycle 3)

Trial Locations (8)

Tisch Cancer Institute at Mount Sinai Medical Center, New York

Virginia Oncology Associates, Norfolk

Indiana University Melvin & Bren Simon Cancer Center, Indianapolis

IU Health Central Indiana Cancer Centers, Indianapolis

IU Health Goshen Hospital, Goshen

Nebraska Cancer Specialists, Omaha

Texas Oncology, PA, Dallas

City of Hope: Duarte, Duarte